FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Valneva SE (NASDAQ: VALN) Receives European Commission Approval of Advance Purchase Agreement for its COVID-19 Vaccine VLA2001”
Valneva SE (NASDAQ: VALN) climbed over 23% in premarket trading after the European Commission approved an Advance Purchase Agreement for its COVID-19 vaccine candidate VLA2001.
The company will provide approximately 27 million doses in 2022 to the EC, which has the option to increase its initial purchase of VLA2001 up to a total of 60 million doses by the end of 2023.
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.
For more information, please visit: Valneva SE
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.